MA33758B1 - Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes - Google Patents

Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes

Info

Publication number
MA33758B1
MA33758B1 MA34878A MA34878A MA33758B1 MA 33758 B1 MA33758 B1 MA 33758B1 MA 34878 A MA34878 A MA 34878A MA 34878 A MA34878 A MA 34878A MA 33758 B1 MA33758 B1 MA 33758B1
Authority
MA
Morocco
Prior art keywords
antagonists
antibody
tnfr1
stable anti
polypeptides
Prior art date
Application number
MA34878A
Other languages
Arabic (ar)
English (en)
Inventor
Silva Inusha De
Armin Sepp
Adriaan Allart Stoop
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33758(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA33758B1 publication Critical patent/MA33758B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne des domaines variables uniques de l'anticorps anti-TNFR1 stable à l'entreposage (d Abs), des antagonistes et des ligands multispécifiques, ainsi que des méthodes et des utilisations de ceux-ci. Les polypeptides anti-TNFR1, les domaines variables uniques de l'anticorps (d Abs), les antagonistes et les ligands multispécifiques sont utiles pour le traitement et/ou la prévention d'une maladie inflammatoire, telle que la BPCO, ainsi que pour l'administration par voie pulmonaire ou orale ou l'acheminement au poumon ou au tractus gastro-intestinal.
MA34878A 2009-10-27 2012-05-18 Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes MA33758B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25523509P 2009-10-27 2009-10-27
PCT/EP2010/066046 WO2011051217A1 (fr) 2009-10-27 2010-10-25 Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes

Publications (1)

Publication Number Publication Date
MA33758B1 true MA33758B1 (fr) 2012-11-01

Family

ID=43382391

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34878A MA33758B1 (fr) 2009-10-27 2012-05-18 Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes

Country Status (26)

Country Link
US (1) US20150210767A1 (fr)
EP (1) EP2493504B1 (fr)
JP (1) JP2013507978A (fr)
KR (1) KR20120101417A (fr)
CN (1) CN102686239B (fr)
AR (1) AR078763A1 (fr)
AU (1) AU2010311640B2 (fr)
BR (1) BR112012010114A2 (fr)
CA (1) CA2777312A1 (fr)
CL (1) CL2012001055A1 (fr)
CO (1) CO6612254A2 (fr)
CR (1) CR20120197A (fr)
DO (1) DOP2012000113A (fr)
EA (1) EA022898B1 (fr)
ES (1) ES2552177T3 (fr)
IL (1) IL218860A0 (fr)
MA (1) MA33758B1 (fr)
MX (1) MX2012005024A (fr)
NZ (1) NZ599114A (fr)
PE (1) PE20121564A1 (fr)
SG (1) SG10201500274TA (fr)
TW (1) TW201125877A (fr)
UA (1) UA107200C2 (fr)
UY (1) UY32969A (fr)
WO (1) WO2011051217A1 (fr)
ZA (1) ZA201203052B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094720A2 (fr) * 2009-02-19 2010-08-26 Glaxo Group Limited Polypeptides, domaines variables d'anticorps, et antagonistes améliorés, tous étant des anti-tnfr1
WO2012172070A1 (fr) * 2011-06-17 2012-12-20 Glaxo Group Limited Antagonistes du récepteur 1 du facteur de nécrose tumorale
CA2897345A1 (fr) * 2013-01-31 2014-08-07 Glaxo Group Limited Procede de production de proteine
WO2015104322A1 (fr) 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Traitement de maladies inflammatoires avec des antagonistes anti-tnfr1 non compétitifs
JP6784775B2 (ja) * 2016-04-05 2020-11-11 ウニヴェルズィテート シュトゥットガルト ｈｕＴＮＦＲ１相互作用の一価阻害剤
IL300930A (en) 2020-08-27 2023-04-01 Enosi Therapeutics Corp Methods and compositions for the treatment of autoimmune diseases and cancer
WO2022117569A1 (fr) 2020-12-02 2022-06-09 Oncurious Nv Anticorps antagoniste de ccr8 en combinaison avec un anticorps agoniste du récepteur bêta de la lymphotoxine en thérapie contre le cancer
CN114699533B (zh) * 2022-05-06 2023-05-09 郑州大学 一种核酸适配体和多肽交联的双靶点复合核酸纳米药物制备方法与应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1994026087A2 (fr) 1993-05-14 1994-11-24 Connor Kim C O Production de proteines de recombinaison, culture de cellules d'insectes et procede s'y rapportant
WO1994029351A2 (fr) 1993-06-16 1994-12-22 Celltech Limited Anticorps
AU736836B2 (en) 1997-07-07 2001-08-02 Medical Research Council In vitro sorting method
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
EP1263788A2 (fr) 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification d'un nouveau domaine dans la famille des recepteurs du facteur de necrose tumorale mediant l'assemblage et la fonction du recepteur de pre-ligand
WO2003002609A2 (fr) 2001-06-28 2003-01-09 Domantis Limited Ligand
WO2003076567A2 (fr) 2002-03-05 2003-09-18 Eli Lilly And Company Proteines hybrides g-csf heterologues
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
CA2505326A1 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Procede d'administration de polypeptides therapeutiques et polypeptides associes
EP1578801A2 (fr) 2002-12-27 2005-09-28 Domantis Limited Anticorps a domaine unique ayant une double specificite pour un ligand et son recepteur
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1627062A1 (fr) 2003-05-14 2006-02-22 Domantis Limited Procede de recuperation de polypeptides qui se deplient de facon reversible a partir d'un repertoire de polypeptides
ES2315664T3 (es) 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
PL1729795T3 (pl) 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
CN101084014A (zh) * 2004-10-08 2007-12-05 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2688434A1 (fr) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, domaines variables d'anticorps et antagonistes
WO2010094720A2 (fr) * 2009-02-19 2010-08-26 Glaxo Group Limited Polypeptides, domaines variables d'anticorps, et antagonistes améliorés, tous étant des anti-tnfr1
EP3330287B1 (fr) * 2009-02-19 2019-12-18 Glaxo Group Limited Variants de liaison anti-albumine sérique améliorés

Also Published As

Publication number Publication date
AR078763A1 (es) 2011-11-30
ES2552177T3 (es) 2015-11-26
AU2010311640B2 (en) 2015-01-29
CN102686239B (zh) 2016-02-03
KR20120101417A (ko) 2012-09-13
UA107200C2 (uk) 2014-12-10
AU2010311640A1 (en) 2012-05-10
CA2777312A1 (fr) 2011-05-05
EA022898B1 (ru) 2016-03-31
WO2011051217A1 (fr) 2011-05-05
EP2493504A1 (fr) 2012-09-05
ZA201203052B (en) 2013-09-25
CR20120197A (es) 2012-06-22
EA201290172A1 (ru) 2013-04-30
CO6612254A2 (es) 2013-02-01
UY32969A (es) 2011-05-31
BR112012010114A2 (pt) 2017-08-08
CL2012001055A1 (es) 2012-10-05
EP2493504B1 (fr) 2015-10-07
TW201125877A (en) 2011-08-01
IL218860A0 (en) 2012-06-28
DOP2012000113A (es) 2012-08-15
NZ599114A (en) 2014-09-26
US20150210767A1 (en) 2015-07-30
JP2013507978A (ja) 2013-03-07
MX2012005024A (es) 2012-09-07
PE20121564A1 (es) 2012-11-29
CN102686239A (zh) 2012-09-19
SG10201500274TA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
MA33758B1 (fr) Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes
MA31403B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
MA31437B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
MA30337B1 (fr) Anticorps
MA34461B1 (fr) Anticorps anti-peptide beta-amyloide n3pgiu et leurs utilisations
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA29723B1 (fr) Composes
MA31898B1 (fr) Compositions pharmaceutiques
MA33339B1 (fr) Utilisation d'un anticorps anti-tau ps422 pour le traitement de maladies cérébrales
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
DE602005021072D1 (de) Adzyme und deren verwendungen
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MA33221B1 (fr) Fusions de médicament et conjugués afférents
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
MA47392A1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren